Want to see IN:NEULANDLAB full AI Analyst Report?
Top Page
Neuland Laboratories Ltd.
(NEULANDLAB)
Select Model
Select Model
Rating:66Neutral
Price Target:
₹21,277.00
▲(14.57% Upside)
Action:Reiterated
Date:08/09/26
The score is driven primarily by solid fundamentals (strong profitability and a conservatively leveraged balance sheet), but is held back by weaker cash flow quality (negative FY2026 free cash flow) and a demanding valuation (high P/E with minimal dividend support). Technically, momentum is strong, though overbought indicators suggest elevated short-term pullback risk.
Positive Factors
Conservative Balance Sheet
Low leverage gives Neuland financial resilience and preserves capacity to fund growth, absorb operating volatility, or manage weaker periods without excessive refinancing pressure. Steadily expanding equity and strong prior returns on equity also support the quality and durability of its capital structure.
Negative Factors
Negative Free Cash Flow
Negative free cash flow reduces near-term financial flexibility even when reported profits remain strong. If elevated investment or working-capital requirements persist, Neuland may have less internally generated cash available for expansion, debt reduction, or shareholder distributions over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage gives Neuland financial resilience and preserves capacity to fund growth, absorb operating volatility, or manage weaker periods without excessive refinancing pressure. Steadily expanding equity and strong prior returns on equity also support the quality and durability of its capital structure.
Read all positive factors
Neuland Laboratories Ltd. (NEULANDLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹252.76B
Dividend Yield0.17%
Average Volume (3M)3.94K
Price to Earnings (P/E)50.8
Beta (1Y)1.25
Revenue Growth78.33%
EPS Growth182.61%
CountryIN
Employees1,643
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)387.97
Shares Outstanding12,829,889
10 Day Avg. Volume2,560
30 Day Avg. Volume3,939
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)359.83
Revenue Forecast (FY)₹24.10B
Neuland Laboratories Ltd. Business Overview & Revenue Model
Company Description
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial component...
How the Company Makes Money
Neuland Laboratories primarily makes money by selling pharmaceutical APIs and by providing contract development and manufacturing services tied to APIs and advanced intermediates.
1) API / bulk drug sales (product-driven revenue): The company man...
Neuland Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
78
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.72B | 20.23B | 14.34B | 15.16B | 11.61B | 9.23B |
| Gross Profit | 11.85B | 6.43B | 6.84B | 7.82B | 5.47B | 3.70B |
| EBITDA | 7.94B | 6.05B | 4.18B | 4.72B | 2.79B | 1.41B |
| Net Income | 4.98B | 3.64B | 2.60B | 3.00B | 1.64B | 638.22M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 29.30B | 21.80B | 18.33B | 15.80B | 13.83B |
| Cash, Cash Equivalents and Short-Term Investments | 766.70M | 3.55B | 3.67B | 1.03B | 454.16M | 84.68M |
| Total Debt | 0.00 | 3.01B | 1.57B | 953.90M | 1.28B | 2.41B |
| Total Liabilities | -18.74B | 10.56B | 6.55B | 5.50B | 5.86B | 5.43B |
| Stockholders Equity | 18.74B | 18.74B | 15.25B | 12.83B | 9.94B | 8.41B |
Cash Flow | ||||||
| Free Cash Flow | -2.07B | -588.87M | 1.11B | 1.18B | 1.71B | -372.97M |
| Operating Cash Flow | -367.47M | 3.38B | 3.17B | 2.61B | 2.37B | 603.89M |
| Investing Cash Flow | -521.95M | -4.32B | -2.98B | -1.50B | -614.99M | -955.16M |
| Financing Cash Flow | -19.30M | 380.18M | 249.61M | -692.82M | -1.36B | 377.21M |
Neuland Laboratories Ltd. Technical Analysis
Neutral
18570.85
Price Trends
21751.68
Negative
20482.18
Negative
17384.07
Positive
Market Momentum
-672.91
Negative
41.49
Neutral
72.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Neutral. The current price of 18570.85 is below the 20-day moving average (MA) of 20149.05, below the 50-day MA of 21751.68, and above the 200-day MA of 17384.07, indicating a neutral trend. The MACD of -672.91 indicates Negative momentum. The RSI at 41.49 is Neutral, neither overbought nor oversold. The STOCH value of 72.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:NEULANDLAB.
Neuland Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹172.84B | 28.81 | ― | 0.36% | 8.19% | 26.12% | |
73 Outperform | ₹2.58T | 88.73 | ― | 0.31% | 16.35% | 26.84% | |
69 Neutral | ₹965.37B | 26.27 | ― | 0.24% | 9.09% | 9.61% | |
66 Neutral | ₹252.76B | 50.78 | ― | 0.17% | 78.33% | 182.61% | |
64 Neutral | ₹208.04B | 31.03 | ― | 0.21% | 24.83% | 36.88% | |
60 Neutral | ₹1.29T | 96.96 | ― | 0.08% | 23.03% | 95.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:NEULANDLAB
Neuland Laboratories Ltd.
19,701.10
3,215.13
19.50%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,677.80
539.15
47.35%
IN:DIVISLAB
Divi's Laboratories Limited
9,715.00
2,996.56
44.60%
IN:ALIVUS
Glenmark Life Sciences Limited
1,407.80
505.28
55.98%
IN:GRANULES
Granules India Limited
839.55
275.43
48.82%
IN:LAURUSLABS
Laurus Labs Ltd.
2,392.00
1,438.45
150.85%
Neuland Laboratories Ltd. Corporate Events
Neuland Laboratories Opens Special Window for Dematerialization of Physical Shares
Oct 24, 2026
Neuland Laboratories Ltd. has notified the stock exchanges that it has published newspaper advertisements announcing the opening of a special window for the transfer and dematerialization of physical shares. The move, undertaken in line with a rec...
Neuland Unit 3 Inspection Closed After U.S. FDA Issues EIR
Oct 14, 2026
Neuland Laboratories Ltd. has announced that the U.S. Food and Drug Administration has issued an Establishment Inspection Report for its Unit 3 manufacturing facility in Gaddapotharam Village, Sangareddy District. The report follows an inspection ...
Neuland Labs Opens Special Window for Demat of Physical Shares
Aug 23, 2026
Neuland Laboratories Ltd. has notified stock exchanges that it has published newspaper advertisements about the opening of a Special Window for the transfer and dematerialization of physical share certificates. The move, undertaken in line with a ...
Neuland Laboratories Publishes Q1 FY27 Results in Leading Dailies
Aug 6, 2026
Neuland Laboratories Ltd., a listed Indian pharmaceutical company specializing in active pharmaceutical ingredients, serves global generics and innovator firms in regulated markets. It maintains listings on BSE and NSE and follows Indian securitie...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.